THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE
RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED
STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF
SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO
DO SO WOULD BREACH ANY APPLICABLE LAW OR
REGULATION.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS
ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS
SECTION OF THE CIRCULAR TO SHAREHOLDERS OF THE COMPANY DATED 14
MARCH 2024.
Oxford BioDynamics
PLC
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Result of
General Meeting
Director/PDMR Dealings
3 April 2024
- Oxford BioDynamics PLC (AIM: OBD),
a biotechnology company developing precision
medicine tests based on the EpiSwitch® 3D genomics platform
announces that both resolutions proposed at the General
Meeting of the Company, held earlier today, were duly
passed.
Further to the passing of the resolutions at
the General Meeting, application has been made for 18,234,454 new
Ordinary Shares (comprising the VCT/EIS Placing Shares to be issued
pursuant to the Placing) to be admitted to trading on AIM
("VCT/EIS Admission").
Application has also been made for 91,317,781 new Ordinary Shares
(comprising the General Placing Shares, the Subscription Shares and
the PrimaryBid Shares to be issued pursuant to the Placing, the
Subscriptions and the PrimaryBid Offer) to be admitted to trading
on AIM ("General
Admission").
It is expected that VCT/EIS Admission will take
place, and trading in the VCT/EIS Placing Shares will commence, at
8.00 a.m. on 5 April 2024 and that General Admission will take
place, and trading in the General Placing Shares, the Subscription
Shares and the PrimaryBid Shares will commence at 8.00 a.m. on 8
April 2024.
Following VCT/EIS Admission, the Company's issued
ordinary share capital and total voting rights will consist of
220,537,869 Ordinary Shares. Following General Admission, the
Company's issued ordinary share capital and total voting rights
will consist of 311,855,650 Ordinary Shares. These figures should
be used by shareholders as the denominator for the calculation by
which they determine if they are required to notify their interest
in, or a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
The total New Ordinary Shares subscribed for pursuant
to the Placing, the Subscriptions and the PrimaryBid Offer by the
Directors and PDMRs who are participating in the Fundraising, are
set out below:
|
Director/PDMR
|
Existing beneficial
shareholding
|
Fundraising Shares
|
Beneficial shareholding
following the Fundraising
|
Shareholding as a
percentage of the Enlarged Share Capital
|
|
Dr Alexandre Akoulitchev
|
6,603,082
|
333,333
|
6,936,415
|
2.22%
|
|
Dr Jon Burrows
|
700,000
|
388,888
|
1,088,888
|
0.35%
|
|
Stephan Diggle1
|
27,431,756
|
2,222,222
|
29,653,978
|
9.51%
|
|
Thomas Guiel
|
365,000
|
258,888
|
623,888
|
0.20%
|
|
Dr Ewan Hunter
|
136,363
|
55,555
|
191,918
|
0.06%
|
|
Paul Stockdale
|
331,818
|
166,666
|
498,484
|
0.16%
|
|
Matthew Wakefield2
|
1,022,727
|
277,777
|
1,300,504
|
0.42%
|
1 Stephen Diggle's beneficial shareholding is held through the
Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are
controlled by him.
2 Matthew Wakefield's beneficial shareholding includes shares
owned by his wife, Mrs Carla Wakefield.
Following on from the Company's announcement on 13
March 2024, Baden Hill, a related party of the Company, will
receive commission of £167,135 in relation to their role as joint
broker on the Fundraising.
Director/PDMR Dealings
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Matthew Wakefield
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chairman
|
|
b)
|
Initial notification /Amendment
|
Initial
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
Identification code
|
Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.09
|
277,777
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 April 2024
|
|
f)
|
Place of the transaction
|
Off market
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Dr Jon Burrows
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
Identification code
|
Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.09
|
388,888
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 April 2024
|
|
f)
|
Place of the transaction
|
Off market
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Dr Alexandre Akoulitchev
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Scientific Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
Identification code
|
Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.09
|
333,333
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 April 2024
|
|
f)
|
Place of the transaction
|
Off market
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Paul Stockdale
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
Identification code
|
Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.09
|
166,666
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 April 2024
|
|
f)
|
Place of the transaction
|
Off market
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Vulpes Investment Management (a PCA of Stephen
Diggle) through Vulpes Testudo Fund
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Person closely associated with
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1p par value
each
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.09
|
2,222,222
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 April 2023
|
|
f)
|
Place of the transaction
|
Off market
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Thomas Guiel
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Operating Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
Identification code
|
Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.09
|
258,888
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 April 2024
|
|
f)
|
Place of the transaction
|
Off market
|
|
1
|
Details of the
person discharging managerial responsibilities / person closely
associated
|
|
a)
|
Name
|
Dr Ewan Hunter
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Data Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
Identification code
|
Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.09
|
55,555
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 April 2024
|
|
f)
|
Place of the transaction
|
Off market
|
For further
details please contact:
|
Oxford BioDynamics
PLC
Jon
Burrows, CEO
Paul
Stockdale, CFO
|
+44 (0)1865
518910
|
|
Shore Capital - Nominated
Adviser and Joint Broker
Advisory:
Stephane Auton / Iain Sexton
Broking:
Fiona Conroy
|
+44 (0)20
7408 4090
|
|
Baden Hill (a trading name
for Northland Capital Partners Limited) - Joint
Broker
Alex
Schlich
|
+44 (0)20
3951 8907
|
|
WG Partners - Joint
Broker
David
Wilson / Claes Spång / Sateesh Nadarajah / Erland
Sternby
|
+44 (0)20
3705 9330
|
|
Instinctif
Partners
|
Tel: +44
(0)20 7457 2020
|
|
Melanie
Toyne-Sewell / Jack Kincade
|
OxfordBioDynamics@instinctif.com
|
Notes for
Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is
a global biotechnology company, advancing personalized healthcare
by developing and commercializing precision medicine tests for
life-changing diseases.
Its flagship products are
the EpiSwitch®
CiRT (Checkpoint Inhibitor
Response Test) and EpiSwitch®
PSE (EpiSwitch Prostate Screening
test) blood tests. CiRT is a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022. PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or
absence of prostate cancer, which was launched in the US and UK in
September 2023.
In March 2021, the Company launched
its first commercial prognostic test, EpiSwitch®
CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker
discovery, EpiSwitch®
Explorer Array Kit, which is available
for purchase by the life science research community.
The Company's product portfolio is
based on a proprietary 3D genomic biomarker platform, EpiSwitch®,
which can build molecular diagnostic classifiers for the prediction
of response to therapy, patient prognosis, disease diagnosis and
subtyping, and residual disease monitoring in a wide range of
indications.
Oxford BioDynamics has participated
in more than 40 partnerships with big pharma and leading
institutions including Pfizer, EMD Serono, Genentech, Roche,
Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.
The Company has created a valuable
technology portfolio, including biomarker arrays, molecular
diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of
millions of data points from over 15,000 samples in more than 30
human diseases.
OBD is headquartered in Oxford, UK
and is listed on AIM of the London Stock Exchange. It also has a
commercial office in Gaithersburg and a clinical laboratory in
Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.
For more information, please visit
the Company's website, www.oxfordbiodynamics.com,
or follow OBD on Twitter (@OxBioDynamics)
and LinkedIn.